Get the Stockscreener App
5.15
7.39%
-0.40
Gri Bio Inc stock is traded at $5.15, with a volume of 155.21K.
It is down -7.39% in the last 24 hours and down -33.49% over the past month.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
See More
Previous Close:
$5.55
Open:
$5.31
24h Volume:
155.21K
Relative Volume:
1.91
Market Cap:
$2.77M
Revenue:
-
Net Income/Loss:
$-8.26M
P/E Ratio:
-0.0961
EPS:
-53.609
Net Cash Flow:
$-12.17M
1W Performance:
-21.15%
1M Performance:
-33.49%
6M Performance:
-90.78%
1Y Performance:
-98.31%
1-Day Range:
$4.96
$5.44
1-Week Range:
$4.96
$6.37
52-Week Range:
$4.96
$333.20
Gri Bio Inc Stock (GRI) Company Profile
Name
Gri Bio Inc
Sector
Industry
Phone
(619) 400-1171
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA
Compare GRI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRI
Gri Bio Inc
|
5.16 | 2.98M | 0 | -8.26M | -12.17M | -53.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.44 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.51 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
865.92 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
358.61 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
335.92 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Gri Bio Inc Stock (GRI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-24 | Initiated | H.C. Wainwright | Buy |
Gri Bio Inc Stock (GRI) Latest News
GRI Bio secures U.S. composition of matter patent - TipRanks
New GRI Bio patent covers compounds for inflammatory and autoimmune diseases - Stock Titan
Trade Recap: Is DB Gold Double Short ETN stock a buy or sellTrade Signal Summary & Real-Time Market Sentiment Reports - baoquankhu1.vn
Analysis Recap: Can Viavi Solutions Inc withstand a market correction2025 Breakouts & Breakdowns & Smart Investment Allocation Tips - baoquankhu1.vn
Trade Report: Is GRI Bio Inc in a long term uptrendNew Guidance & Consistent Growth Stock Picks - baoquankhu1.vn
GRI Bio To Carry Out 1-for-28 Reverse Stock Split On January 26th, 2026 - 富途牛牛
GRI Bio Announces Reverse Stock Split To Regain Minimum Bid Price Nasdaq Compliance - Nasdaq
GRI Bio announces 1-for-28 reverse stock split to regain Nasdaq compliance - Investing.com
Gri Bio Announces Reverse Stock Split - TradingView
GRI Bio Announces 1-for-28 Reverse Stock Split - TipRanks
GRI Bio stock falls after announcing 1-for-28 reverse split By Investing.com - Investing.com South Africa
GRI Bio stock falls after announcing 1-for-28 reverse split - Investing.com Nigeria
GRI Bio (NASDAQ: GRI) plans 1-for-28 reverse stock split in January - Stock Titan
GRI Bio slashes share count with 1-for-28 split to meet Nasdaq price rule - Stock Titan
GRI Bio conditionally regains Nasdaq compliance with equity listing rule By Investing.com - Investing.com Nigeria
GRI Bio conditionally regains Nasdaq compliance with equity listing rule - Investing.com
GRI Bio Regains Conditional Compliance With Nasdaq Listing Requirements - TipRanks
Short Covering: Is GCTSWS stock a good pick for beginnersJuly 2025 Chart Watch & Expert Approved Trade Ideas - baoquankhu1.vn
GRI Bio shareholders approve reverse stock split and report Nasdaq compliance - Investing.com Nigeria
GRI Bio Shareholders Authorize Reverse Stock Split Plan - TipRanks
GRI Bio (NASDAQ: GRI) wins reverse split approval and addresses Nasdaq equity risk - Stock Titan
GRI: Reverse stock split and adjournment proposals approved; results to be filed on Form 8-K - TradingView
Gains Recap: Why GRI Bio Inc stock remains on watchlistsJuly 2025 Big Picture & Low Risk Investment Opportunities - Bộ Nội Vụ
Options Flow: What insider trading reveals about GRI Bio Inc. stockEarnings Trend Report & Smart Money Movement Alerts - Bộ Nội Vụ
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Market Recap: What makes GRI Bio Inc stock attractive todayJuly 2025 Snapshot & Fast Moving Trade Plans - baoquankhu1.vn
GRI Bio approves reverse stock split, stockholders vote in favor - MSN
GRI Bio, Inc.Common Stock (NQ: GRI - FinancialContent
GRI Bio announces pricing of $8M public offering - MSN
GRI Bio increases at-the-market offering capacity to $7.38 million - Investing.com Nigeria
GRI Bio reports positive Phase 2a data for IPF treatment By Investing.com - Investing.com Nigeria
GRI Bio Expands At-The-Market Equity Offering Capacity - TipRanks
GRI Bio, Inc. Increases Share Issuance Limit - TradingView — Track All Markets
Can GRI Bio Inc. stock sustain institutional interestCushioning Options Review & trail grip notes for mixed terrain - ulpravda.ru
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Is GRI Bio Inc. stock affected by interest rate hikesWall Street Watch & Safe Entry Trade Signal Reports - Улправда
Can GRI Bio Inc. stock weather global recession2025 Price Targets & Community Consensus Trade Signals - ulpravda.ru
GRI Bio stock rises on positive Phase 2a immune data for IPF treatment - Investing.com Australia
GRI Bio reports positive Phase 2a data for IPF treatment - Investing.com
GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621 - The Manila Times
GRI Bio, Inc. Announces Positive Phase 2a Trial Data for GRI-0621 - TradingView — Track All Markets
GRI Bio Announces Additional Positive Data from Phase 2a - GlobeNewswire
GRI Bio reports six-week interim safety outcomes from trial of GRI-0621 for IPF - MSN
What Wall Street predicts for GRI Bio Inc. stock priceBullish Engulfing Patterns & Small Entry Portfolio - Улправда
What technical signals suggest for GRI Bio Inc. stock2026 world cup usa national team third place match goalkeepers high defensive line group prediction insights - ulpravda.ru
What drives GRI Bio Inc stock priceEarnings Forecast Updates & High Yield Trading Growth - earlytimes.in
Decliners Report: Is GRI Bio Inc stock attractive for hedge funds2025 Bull vs Bear & Free Community Consensus Stock Picks - moha.gov.vn
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
GRI Bio Inc. (GRI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What insider trading reveals about GRI Bio Inc. stockLong Setup & Real-Time Buy Zone Alerts - Улправда
Gri Bio Inc Stock (GRI) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
0.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):